Recent Comments

Comment RSS

Renal Failure News and Research RSS Feed - Renal Failure News and Research

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.

Mayo Clinic licenses non-exclusive rights to Expression Pathology's Liquid Tissue patent

18. November 2009 00:52
Expression Pathology, a leader in tissue proteomic analysis, today announced Mayo Clinic has licensed non-exclusive rights to Expression Pathology's Liquid Tissue® patent for use in diagnosis of systemic amyloidosis in formalin-fixed tissue. [More]

Posted in: Business / Finance | Medical Patent News

Tags: , , , , , ,

Non-clinical data from Cytokinetics' smooth muscle contractility program presented

17. November 2009 08:27
Cytokinetics, Incorporated announced today that three abstracts summarizing non-clinical data regarding its smooth muscle contractility program were presented at the 2009 Scientific Sessions of the American Heart Association in Orlando, Florida. [More]

Hospitals should expand quality control guidelines to improve surgical complications in older patients

17. November 2009 02:00
The elderly are more vulnerable to problems after a major surgical procedure than younger patients, but a team of investigators using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) suggest that one way to improve surgical results in this age group is to have hospitals expand their quality control guidelines to include more types of surgery-related complications. [More]

Posted in: Healthcare News

Tags: , , , ,

Research reveals new biological function of polycystins in regulating pressure sensing

6. November 2009 04:38
What is the role of proteins called polycystins in patients with polycystic kidney disease? A team of researchers from CNRS and INSERM, led by Eric Honoré from the Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, Université de Nice Sophia Antipolis/CNRS) has elucidated the molecular and cellular mechanisms linked to polycystin malfunctions that cause this common hereditary disease. [More]

Third quarter 2009 financial results announced by Affymax

4. November 2009 08:07
Affymax, Inc. today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008. [More]

Posted in: Business / Finance

Tags: ,

Safeguard Scientifics reports financial results for the third quarter of 2009

4. November 2009 06:33
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008. [More]

New FDA-approved heart pump for high-risk patients

4. November 2009 04:26
Cardiologists at the University of Illinois Medical Center are using a new heart pump that can be inserted without the need for surgery and allows them to treat high-risk patients with a procedure to unblock their heart arteries. [More]

Gilead Sciences to present Viread Phase III clinical trial data

2. November 2009 03:24
Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. [More]

Amgen publishes Phase 3 study results of Aranesp

31. October 2009 05:14
Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. [More]

Data from multiple clinical and preclinical studies evaluating Hematide announced

31. October 2009 00:17
Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients. [More]

Roche discloses the results of first Phase III clinical study using Taspoglutide

29. October 2009 02:45
Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research. [More]

Shire receives European approval for FOSRENOL

28. October 2009 05:19
Shire plc, the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL(R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1.78mmol/L (5.5mg/dL). [More]

Report on the Brigham Renal Board Review Course

24. October 2009 01:32
Research and Markets (http://www.researchandmarkets.com/research/782945/the_brigham_renal) has announced the addition of the "The Brigham Renal Board Review Course" training to their offering. [More]

Posted in: Medical Condition News | Healthcare News

Tags: , , , ,

Modified NAGA: New enzyme for enzyme replacement therapy

23. October 2009 07:11
A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure. The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , ,

Study shows appropriate use of CRRT improves AKI patient outcomes

23. October 2009 03:37
A study appearing today in the New England Journal of Medicine adds to the growing body of evidence supporting continuous renal replacement therapy (CRRT) as the therapy of choice for treatment of acute kidney injury (AKI) patients in the intensive care unit (ICU). [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.